Sunday, June 14, 2026

Latest

Company Overview:

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

[stock_market_chart symbol=”MYM.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$0.12
Market Capitalization (in Millions)$15.09
Last Quarter (Share Data)2/28/2019
Shares Outstanding (in Millions)125.72
Options (in Millions)9.11
Warrants (in Millions)14.09
Fully Diluted (in Millions)148.91
<th<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td
<!DOCTYPEhtml><metaname="google"content="notranslate"><metaname="viewport"content="target-densitydpi=device-dpi,user-scalable=1,minimum-scale=1,maximum-scale=2.5,initial-scale=1,width=device-width"><metahttp-equiv="X-UA-Compatible"content="IE=edge;"><metaname="referrer"content="origin">MYM</td><td class="column-11">Nutraceuticals</td><td class="column-12">-</td><td class="column-13">Google</td><td class="column-14">Drive<linkrel="shortcuticon"href="//ssl.gstatic.com/docs/spreadsheets/favicon3.ico"><linkhref='/static/spreadsheets2/client/css/2968578022-waffle_k_ltr.css'type='text/css'rel='stylesheet'nonce="Fw9E7jRvoxHul7G8hNScZg"><styletype="text/css"nonce="Fw9E7jRvoxHul7G8hNScZg">
html{overflow:visible;}
#sheets-viewport{overflow:auto;}
#sheets-viewport.widget-viewport{overflow:hidden;}
.grid-container{overflow:visible;background:white;}
.grid-table-container{overflow:visible;}
#top-bar{
margin:0;
overflow:hidden;
}
#top-bar{
border-bottom:1pxsolid#ccc;
padding:6px6px0;
}
#doc-title{padding-bottom:5px;}
#doc-title.name{font-size:15px;}
#sheet-menu{
font-size:13px;
margin:6px00;
padding:005px;
}
#sheet-menuli{
display:inline;
list-style-type:none;
margin:0;
padding:5px8px;
}
#sheet-menuli.active{
background-color:#fff;
font-weight:bold;
border:1pxsolid#999;
}
#top-bar#sheet-menuli.active{
border-bottom:0;
}
#sheet-menua,#sheet-menua:visited{color:#07c;}
#footer{
background:#f0f0f0;
border-top:1px#cccsolid;
border-bottom:1px#cccsolid;
font-size:13;
padding:10px10px;
}
.dash{
padding:06px;
}
.ritz.wafflea{color:inherit;}.ritz.waffle.s1{background-color:#ffffff;text-align:center;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}.ritz.waffle.s0{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">
varactiveSheetId;
functionswitchToSheet(id){
if(document.getElementById('sheet-menu')){
document.getElementById('sheet-button-'+activeSheetId)
.className='';
document.getElementById('sheet-button-'+id).className='active';
}
document.getElementById(activeSheetId).style.display='none';
document.getElementById(id).style.display='';
activeSheetId=id;
//posObjs()isdefinedinembeddedObjectJs(seeEmbeddedObjectHtmlBuilder.java)
posObjs();
returnfalse;
}
functioninit(){
varoptPageSwitcher;
functionresize(){
varoptMobileWebHeader=document.getElementById('docs-ml-header-id');
varoptTopBar=document.getElementById('top-bar');
varoptFooter=document.getElementById('footer');
varsheetsViewport=document.getElementById('sheets-viewport');
if(optMobileWebHeader){
sheetsViewport.style.marginTop=optMobileWebHeader.offsetHeight+
(optTopBar?optTopBar.offsetHeight:0)+'px';
}
varadjustedHeight=window.innerHeight-
(optTopBar?optTopBar.offsetHeight:0)-
(optFooter?optFooter.offsetHeight:0);
varadjustedWidth=window.innerWidth;
sheetsViewport.style.width=(adjustedWidth+'px');
sheetsViewport.style.height=(adjustedHeight+'px');
if(optPageSwitcher){
optPageSwitcher.resize(adjustedWidth,adjustedHeight);
}
}
resize();
window.onresize=resize;
varcurrentUrl=window.location.href;
varnewUrl=currentUrl.replace('?sle=true&','?');
newUrl=newUrl.replace('?sle=true','');
newUrl=newUrl.replace('&sle=true&','&');
newUrl=newUrl.replace('&sle=true','');
window.history.replaceState(null,'',newUrl);
}
<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">_docs_flag_initialData={"docs-mwid":false,"docs-smheo":false,"info_params":{"includes_info_params":true},"ilcm":{"eui":"ADFN-ctoHzWx9j47QMwHvC0oA13I7GJCkxvKJTCVQTTUU5ZYqxEV1bNi0EwGJn7mYxWxdHBMXlSK","je":1,"sstu":1623926851831000,"si":"CNSQlPm-nvECFVaGqwcd6RgGyw","gsc":0,"ei":[5707711,5703186,5731094,5708862,5705301,5714628,5707197,5728103,5737700,5700019,5713152,5723284,5717118,5704063,5711808,5710677,5709709,5737898,5733710,5714961,5715515,5709892,5707385,5708480,5709381,5707047,5715399,5715637,5719170,5706133,5714843,5716141,5738168,5703913,5723871,5712352,5702767,5707943,5702912,5710637,5711708,5711850,5720479,5737401,5720568,5725052,5722301,5712033,5704621,5704883,5700559,5721815,5719212,5707609,5710645,5717949,5713207,5711471,5739056,5701903,5724085,5702135,5708574,5721004,5708886,5733973,5706601,5733570,5737254,5713227,5728335,5732963,5725300,5725338,5720788,5713681,5705777,5714796,5712469,5716149,5700884,5714326,5724916,5709476,5711765,5713195,5728567,5716028,5704144,5720487,5735134,5715364,5707986,5720483,5710746,5706169,5711550,5712929,5720925,5711099,5721764,5704641,5711155,5720595,5728475,5702849,5719535,5713597,5714322,5720516,5717161,5713223,5707204,5705040,5701034,5707856,5711012,5703837,5730285,5713049,5712909,5735509,5714674,5702445,5714967,5734352,5713605,5710476,5711957,5720714,5703591,5727257,5724896,5708974,5706933,5710938,5724533,5703027,5729546,5712905,5711297,5722346,5712525,5710933,5713542,5728515,5707445,5710542,5715641,5702785,5712298,5708870,5719527,5714330,5735281,5728083,5711685,5722409,5715222,5727901,5731530,5719462,5709661,5727063,5721344,13702623,5706069,5710893,5712211,5731412,5712477,5703839,5711826,5717070,5713191,5730290,5727853,5716457,5702936,5705223,5706270,5731783,5711524,5713554,5707819,5703022,5703815,5703182,5719482,5712373,5711769,5725742,5737153,5734571,5705493,5720060,5700422,5721012,5719531,5714839,5726110,5705581,5712913,5709357,5735670,5722370,5719651,5711230,5704581,5728945,5711889,5715246,5725511,5727042,5712635,5707425,5706523,5721361,5719502,5700446,5728807,5722189,5719418,5706661,5734994,5722567,5714445,5710692,5736924,5714550,5713333,5701650,5726190,5703762,5721307,5726595,5714310,5707137,5712473,5715824,5709447,5730867,5705649,5716416,5703259,5738433,5735806,5709085,5713211,5701594,5723679,5729072,5706007,5706751,5729206,5716145,5713657,5707657,5735630,5723365,5727624],"crc":0,"cvi":[]},"drive_url":"//drive.google.com?usp\u003dsheets_web","docs-ehr":true,"docs-sup":"/spreadsheets"};_docs_flag_cek='';if(window['DOCS_timing']){DOCS_timing['ifdld']=newDate().getTime();}<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">document.addEventListener('DOMContentLoaded',init);<bodyclass="docs-gm"><divid="top-bar"><divid="doc-title"><spanclass="name">MYMNutraceuticals:KeyShareInfo2<divid="sheets-viewport"><divid="1294638516"style="display:none;position:relative;"dir="ltr"><divclass="ritzgrid-container"dir="ltr"><tableclass="waffle"cellspacing="0"cellpadding="0">
class="row-headerfreezebar-origin-ltrheader-shimrow-header-shim"><thid="1294638516C0"style="width:191px;"class="header-shim"><thid="1294638516C1"style="width:100px;"class="header-shim">
style="height:20px"><thid="1294638516R0"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">1<tdclass="s0">EnterpriseValue(inMIllions)class="s1">$14.24
style="height:20px"><thid="1294638516R1"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">2<tdclass="s0">TTMRevenueclass="s1">$1.78
style="height:20px"><thid="1294638516R2"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">3<tdclass="s0">TTMGrowthMargin%class="s1">65.27%
style="height:20px"><thid="1294638516R3"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">4<tdclass="s0">TTMOperatingExpensesclass="s1">$16.26
style="height:20px"><thid="1294638516R4"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">5<tdclass="s0">TTMOCFclass="s1">-$8.63
style="height:20px"><thid="1294638516R5"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">6<tdclass="s0">P/STTMclass="s1">8.47
style="height:20px"><thid="1294638516R6"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">7<tdclass="s0">P/S(LastQuarterRunRate)class="s1">#DIV/0!
<divid="footer">Publishedby<atarget="_blank"title="LearnmoreaboutGoogleSheets"href="https://docs.google.com/spreadsheets/?usp=sheets_web">GoogleSheets<spanclass="dash">–<ahref="https://docs.google.com/abuse?id=AKkXjoxJPPdT2XZQJ9j1xk56iAncfZHswcfOdDDCv4pDyGeDPRtPlG4JrPFvJQk1Nj2IigePBFtgXVU3uPjrW-o:0">ReportAbuse<spanclass="dash">–Updatedautomaticallyevery5minutes
<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">activeSheetId='1294638516';switchToSheet('1294638516');

Key Balance Sheet Information (in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.11$0.32$0.55$0.27$2.04$10.11$6.63$1.74$0.91$1.72
Biological Assets
Inventory$0.04$0.03$0.06$0.10$1.06$1.11$0.81$0.77
Total Assets$0.13$0.49$1.77$2.12$6.62$20.45$21.11$22.50$20.27$20.04
Net Tangible Assets$0.12$0.48$0.87$1.05$4.99$16.89$17.22$18.61$17.17$16.94
Intangibles/Goodwill$0.00$0.00$0.90$1.07$1.63$3.56$3.89$3.89$3.10$3.10
Total Liabilities$0.42$0.35$0.26$0.25$0.57$1.28$1.20$2.95$1.16$0.87

Key Operating Items (Quarterly in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.14$0.28$0.40$0.48$1.78
Change in Fair Value of Biologial Assets
Gross Margin$0.06$0.19$0.25$0.40$1.16
Marketing and Sales
Investor Relations$0.00$0.01$0.02$0.12$0.32$0.58$1.570.230.34$0.43
Total Operating Expenses$0.04$0.10$0.88$0.79$1.25$2.20$6.782.732.78$3.98
Operating Cash Flow (Quarterly)-$0.03-$0.21-$0.43-$1.09-$1.60-$3.75-4.08-$0.80
Investing Cash Flow (Quarterly)-$0.07$0.02-$1.70-$2.70-$1.88-1.61-$0.03
Financing Cash Flow (Quarterly)$0.00$0.48$0.64$4.56$12.36$2.154.87$1.64

Listing Statement

Video Articles

The Canadian Dream Is Leaving Canada | Spencer Gatten

Allied Gold: The Zijin Deal Is On The Rocks

Why Silver’s Drop May Not Mean the Bull Market Is Over | Peter Krauth

Recommended

Silver47 Starts 10,000 Metre Campaign at Flagship Alaska Silver Project

Blue Jay Gold Launches 16,000 Metre Drill Program At Steller